1. Home
  2. Author
  3. Kim KP

Kim KP

References (2)

Title : Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease - An_2025_Mol.Neurodegener_20_110
Author(s) : An H , Kang S , Shin J , Kim P , Kim S , Im S , Kim JH , Lee KW , Kim DH , Park JH , Park MH , Lee J , Park SK , Kim KP , Lee HM , Lee JH , Choi LS , Jeon HJ , Kim SY , Hwang IY , Bhalla M , Won W , Park HS , Yoo SK , Lee BD , Lee CJ , Pak YK
Ref : Mol Neurodegener , 20 :110 , 2025
Abstract :
PubMedSearch : An_2025_Mol.Neurodegener_20_110
PubMedID: 41107874

Title : Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study - Lim_2008_Clin.Ther_30_1817
Author(s) : Lim KS , Kim JR , Choi YJ , Shin KH , Kim KP , Hong JH , Cho JY , Shin HS , Yu KS , Shin SG , Kwon OH , Hwang DM , Kim JA , Jang IJ
Ref : Clin Ther , 30 :1817 , 2008
Abstract :
PubMedSearch : Lim_2008_Clin.Ther_30_1817
PubMedID: 19014837